ERBB2 and diabetes mellitus: While we observe higher mortality for HER2-enriched tumours in complete case analysis these estimates were attenuated upon imputation for tumour characteristics suggesting current treatment may be sufficient, however, there is some suggestion that other treatment approaches may be warranted to improve outcomes in women with diabetes and breast cancer that should be pursued in future research30.